Grufity logoGrufity logo

CDXS

5.41USD-0.03(-0.55%)Market Closed

Codexis Inc

Market Summary

USD5.41-0.03Market Closed
-0.55%

CDXS Alerts

CDXS Stock Price

RSI Chart

Valuation

Market Cap

372.0M

Price/Earnings

-19.64

Price/Sales

2.76

Price/Cashflow

-28.84

MarketCap/EBT

-19.95

Price/Sales

Profitability

EBT Margin

-13.81%

Return on Equity

-11.88%

Return on Assets

-8.06%

Fundamentals

Revenue

Revenue (TTM)

132.7M

Revenue Y/Y

-6.25%

Revenue Q/Q

-10.25%

Earnings

Earnings (TTM)

-31.2M

Earnings Y/Y

-545.28%

Earnings Q/Q

-278.48%

Price Action

52 Week Range

4.8139.21
(Low)(High)

Last 7 days

7.1%

Last 30 days

-6.7%

Last 90 days

-26.6%

Trailing 12 Months

-85.2%

Financial Health

Current Ratio

4.84

Investor Care

Shares Dilution (1Y)

1.25%

Diluted EPS (TTM)

-0.48

Peers (Alternatives to Codexis)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
41.1B
6.7B
14.00% 3.09%
30.93
6.17
8.42% 34.14%
36.7B
4.7B
-7.73% -40.09%
-1.9K
7.81
9.79% -558.28%
28.5B
3.9B
14.80% -4.52%
34.68
7.36
7.75% 11.02%
11.6B
1.1B
12.28% -28.88%
42.59
10.48
13.51% 65.31%
10.1B
801.3M
-5.83% -36.88%
63.34
12.97
35.20% 39.92%
MID-CAP
SMALL-CAP
2.0B
137.0M
14.63% -56.78%
-9.53
14.05
12.61% -709.53%
1.1B
159.7M
8.70% -71.21%
-4.68
6.81
19.67% -35.56%
661.5M
23.3M
-12.60% -45.72%
-6.25
28.36
76.56% -106.44%
488.2M
135.3M
-43.15% -85.19%
-3.51
3.42
-2.59% -32.75%
413.2M
110.0M
8.29% -73.27%
-5.25
3.72
3.37% -106.72%
372.0M
132.7M
-6.72% -85.20%
-19.64
2.76
31.03% -107.73%
109.5M
118.0M
- -66.15%
-29.97
0.91
0.97% -269.58%
105.9M
68.8M
15.65% -66.00%
-3.75
1.53
5.65% 26.86%
95.7M
51.6M
-4.83% -20.62%
238.75
1.86
20.72% 150.31%

Financials for Codexis

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-1.7%133135122105101
  S&GA Expenses0.2%5251544946
  R&D Expenses9.5%7770645650
Earnings Before Taxes-66.2%-30.98-18.65-20.37-21.09-14.88
Net Income-64.6%-31.18-18.94-20.57-21.28-15.01
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets0.1%235235235246228
  Current Assets0.5%146145145162174
    Cash Equivalents20.6%1099094117119
  Inventory-5.5%22211
  Net PPE-1.6%2324232116
  Goodwill1.3%33333
Liabilities7.5%8176778258
  Current Liabilities6.3%3230293333
Shareholder's Equity-3.3%154159159164169
  Retained Earnings-2.5%-408.69-398.69-396.05-387.70-377.51
  Additional Paid-In Capital0.8%563558555552547
Accumulated Depreciation3.2%3938373635
Shares Outstanding0.2%6665656565
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations154.5%7-12.90-19.01-14.27-16.42
  Share Based Compensation11.5%1513131210
Cashflow From Investing33.7%-19.09-28.78-28.97-21.42-18.43
Cashflow From Financing-32.7%222483

Risks

What is the probability of a big loss on CDXS?

99.2%


Probability that Codexis stock will be more than 20% underwater in next one year

62.7%


Probability that Codexis stock will be more than 30% underwater in next one year.

47.3%


Probability that Codexis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CDXS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Codexis was unfortunately bought at previous high price.

Returns

Cumulative Returns on CDXS

9.8%


10-Year Cumulative Returns

5.1%


7-Year Cumulative Returns

-2.8%


5-Year Cumulative Returns

-29.6%


3-Year Cumulative Returns

What are the long-term rolling returns for CDXS?

FIve years rolling returns for Codexis.

Which funds bought or sold CDXS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.66
-342,000
453,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-70,000
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
-71,000
97,000
-%
2022-11-15
Pier Capital, LLC
REDUCED
-99.86
-4,541,000
4,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
154.93
200,524
620,974
-%
2022-11-15
JACOBS LEVY EQUITY MANAGEMENT, INC
NEW
-
8,046,000
8,046,000
0.06%
2022-11-15
BURNEY CO/
ADDED
15
-70,000
139,000
0.01%
2022-11-15
ALGERT GLOBAL LLC
ADDED
87.48
141,000
1,776,000
0.11%
2022-11-15
ALLIANCEBERNSTEIN L.P.
ADDED
2.96
-253,000
373,000
-%
2022-11-15
JANE STREET GROUP, LLC
NEW
-
63,000
63,000
-%

1–10 of 47

Latest Funds Activity

Are funds buying CDXS calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own CDXS

Codexis News

Stocks Register

Codexis Inc. (CDXS): A Potential Upside Of -306.65 Percent.37 hours ago

Thehour.com

CDXS Fair Value

Recent SEC filings of Codexis

View All Filings
Date Filed Form Type Document
Nov 17, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading
Nov 09, 2022
3
Insider Trading
Nov 04, 2022
10-Q
Quarterly Report
Nov 03, 2022
8-K
Current Report
Oct 31, 2022
4
Insider Trading
Oct 07, 2022
4
Insider Trading
Oct 05, 2022
3
Insider Trading
Oct 05, 2022
4
Insider Trading
Oct 03, 2022
8-K
Current Report

Latest Insider Trading transactions for CDXS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-16
NICOLS JOHN J
SOLD
-227,312
6.3648
-35,714
-
2022-11-16
NICOLS JOHN J
ACQUIRED
70,356.6
1.97
35,714
-
2022-11-15
NICOLS JOHN J
SOLD
-270,238
6.7923
-39,786
-
2022-10-28
NICOLS JOHN J
SOLD
-197,649
5.5339
-35,716
-
2022-10-28
NICOLS JOHN J
ACQUIRED
70,360.5
1.97
35,716
-
2022-10-27
NICOLS JOHN J
SOLD
-225,921
5.6784
-39,786
-
2022-08-15
NICOLS JOHN J
ACQUIRED
90,480
2.32
39,000
-
2022-08-15
NICOLS JOHN J
SOLD
-342,580
8.7841
-39,000
-
2022-08-12
NICOLS JOHN J
ACQUIRED
89,320
2.32
38,500
-
2022-08-12
NICOLS JOHN J
SOLD
-331,774
8.6175
-38,500
-

1–10 of 50

John J. Nicols
260
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CDXS Income Statement

2022-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenues$ 34,470$ 36,769$ 108,215$ 80,253
Costs and operating expenses:    
Cost of product revenue9,7866,86729,57715,403
Research and development21,82115,16560,41039,562
Selling, general and administrative13,49913,40739,85937,600
Total costs and operating expenses45,10635,439129,84692,565
Income (loss) from operations(10,636)1,330(21,631)(12,312)
Interest income43641618424
Other income, net216983150920
Income (loss) before income taxes(9,984)2,354(20,863)(10,968)
Provision for income taxes8110125121
Net income (loss)$ (9,992)$ 2,244$ (20,988)$ (11,089)
Net income (loss) per share, basic (in dollars per share)$ (0.15)$ 0.03$ (0.32)$ (0.17)
Net income (loss) per share, diluted (in dollars per share)$ (0.15)$ 0.03$ (0.32)$ (0.17)
Weighted average common stock shares used in computing net income (loss) per share, basic (in shares)65,42664,62865,27164,452
Weighted average common stock shares used in computing net income (loss) per share, diluted (in shares)65,42667,74165,27164,452
Product revenue    
Revenues:    
Total revenues$ 28,042$ 28,731$ 93,376$ 53,674
Research and development revenue    
Revenues:    
Total revenues$ 6,428$ 8,038$ 14,839$ 26,579

CDXS Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 108,689$ 116,797
Restricted cash, current528579
Financial assets:  
Accounts receivable16,52724,953
Contract assets5,8674,557
Unbilled receivables7,4908,558
Total financial assets29,88438,068
Less: allowances(109)(416)
Total financial assets, net29,77537,652
Inventories1,6231,160
Prepaid expenses and other current assets5,3825,700
Total current assets145,997161,888
Restricted cash1,5201,519
Investment in non-marketable equity securities ($13,921 and $12,713 with a related party)20,51014,002
Right-of-use assets - Operating leases, net40,49344,095
Right-of-use assets - Finance leases, net017
Property and equipment, net23,31921,345
Goodwill3,2413,241
Other non-current assets208276
Total assets235,288246,383
Current liabilities:  
Accounts payable2,6212,995
Accrued compensation9,46311,119
Other accrued liabilities12,99212,578
Current portion of lease obligations - Operating leases5,2304,093
Deferred revenue ($0 and $245 to a related party)1,6022,586
Total current liabilities31,90833,371
Deferred revenue, net of current portion8,2383,749
Long-term lease obligations - Operating leases39,65543,561
Other long-term liabilities1,3561,311
Total liabilities81,15781,992
Commitments and Contingencies (Note 10)
Stockholders' equity:  
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding00
Common stock, $0.0001 par value per share; 100,000 shares authorized; 65,613 shares and 65,109 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively66
Additional paid-in capital562,811552,083
Accumulated deficit(408,686)(387,698)
Total stockholders' equity154,131164,391
Total liabilities and stockholders' equity$ 235,288$ 246,383